Cargando…

Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) causes significant mortality globally. The majority of patients experience resistance to systemic therapies and often undergo recurrence or disease progression even after aggressive local therapies. Management of HCC is determined by the extent and stag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nyakale, Nozipho, Filippi, Luca, Aldous, Colleen, Sathekge, Mike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093680/ https://www.ncbi.nlm.nih.gov/pubmed/37046636 http://dx.doi.org/10.3390/cancers15071975

Ejemplares similares

Segmented linear correlations between bone scan index and prostate cancer biomarkers, alkaline phosphatase, and prostate specific antigen in patients with a Gleason score ≥7
por: Tasmeera, Ebrahim, et al.
Publicado: (2022)

Comparing (99m)Tc-PSMA to (99m)Tc-MDP in Prostate Cancer Staging of the Skeletal System
por: Kabunda, Joseph, et al.
Publicado: (2021)

A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update
por: Dewulf, Jonatan, et al.
Publicado: (2020)

Utility of 18F FDG-PET in Parkinsonism in an African population
por: Amod, Ferzana Hassan, et al.
Publicado: (2022)

FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma
por: Gilardi, Laura, et al.
Publicado: (2023)

PET Radiopharmaceuticals
por: Shahhosseini, Soraya
Publicado: (2011)

Radiopharmaceuticals for PET imaging: issue A
por: Roivainen, Anne, et al.
Publicado: (2020)

New SPECT and PET Radiopharmaceuticals for Imaging Cardiovascular Disease
por: Sogbein, Oyebola O., et al.
Publicado: (2014)

PET Radiopharmaceuticals for Specific Bacteria Imaging: A Systematic Review
por: Auletta, Sveva, et al.
Publicado: (2019)

Insight into the Development of PET Radiopharmaceuticals for Oncology
por: Lau, Joseph, et al.
Publicado: (2020)

PET Radiopharmaceuticals for Imaging Chemotherapy-Induced Cardiotoxicity
por: Sivapackiam, Jothilingam, et al.
Publicado: (2020)

Head-to-Head Comparison between Peptide-Based Radiopharmaceutical for PET and SPECT in the Evaluation of Neuroendocrine Tumors: A Systematic Review
por: Poletto, Giulia, et al.
Publicado: (2022)

SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic
por: Wang, Xiaobo, et al.
Publicado: (2017)

PET Oncological Radiopharmaceuticals: Current Status and Perspectives
por: Lin, Mai, et al.
Publicado: (2022)

Scintigraphic peritoneography in the diagnosis of pleuroperitoneal leak complicating peritoneal dialysis: A comparison with conventional diagnostic methods
por: Harry, Lerwine, et al.
Publicado: (2020)

Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68
por: Cusnir, Ruslan, et al.
Publicado: (2017)

Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
por: Crișan, George, et al.
Publicado: (2022)

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2019)

PET Radiopharmaceuticals for Imaging Integrin Expression: Tracers in Clinical Studies and Recent Developments
por: Haubner, Roland, et al.
Publicado: (2014)

Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications()
por: Franquet, Elisa, et al.
Publicado: (2022)

Will extended field-of-view PET/CT depopulate the graveyard of failed PET radiopharmaceuticals?
por: de Vries, E. F. J., et al.
Publicado: (2022)

The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review
por: Rizzo, Alessio, et al.
Publicado: (2023)

Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis
por: Rizzo, Alessio, et al.
Publicado: (2022)

Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors
por: Nguyen, Anh Thu, et al.
Publicado: (2023)

Methods to Enhance the Metabolic Stability of Peptide-Based PET Radiopharmaceuticals
por: Evans, Brendan J., et al.
Publicado: (2020)

Current Status of (68)Ga-Pentixafor in Solid Tumours
por: Hadebe, Bawinile, et al.
Publicado: (2022)

Radiopharmaceutical tracers for cardiac imaging
por: Manabe, Osamu, et al.
Publicado: (2017)

Development of Folate Receptor−Targeted PET Radiopharmaceuticals for Tumor Imaging—A Bench-to-Bedside Journey
por: Boss, Silvan D., et al.
Publicado: (2020)

Characterization of FDG PET Images Using Texture Analysis in Tumors of the Gastro-Intestinal Tract: A Review
por: Deleu, Anne-Leen, et al.
Publicado: (2020)

Quantitative comparative analysis of amyloid PET images using three radiopharmaceuticals
por: Jeong, Young Jin, et al.
Publicado: (2023)

Multifarious Ga-68 Labeled PET Radiopharmaceuticals in Imaging Various Malignancies
por: Vatsa, Rakhee, et al.
Publicado: (2018)

SPECT/CT and PET/CT, related radiopharmaceuticals, and areas of application and comparison
por: Alqahtani, Fawaz F.
Publicado: (2023)

Intracranial Solitary Fibrous Tumor: A “New” Challenge for PET Radiopharmaceuticals
por: Sardaro, Angela, et al.
Publicado: (2022)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Stroma Targeting Nuclear Imaging and Radiopharmaceuticals
por: Shetty, Dinesh, et al.
Publicado: (2012)

A Generator-Produced Gallium-68 Radiopharmaceutical for PET Imaging of Myocardial Perfusion
por: Sharma, Vijay, et al.
Publicado: (2014)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

Metastatic Papillary Thyroid Carcinoma in a Paediatric Patient
por: Mothata, Nthabiseng Ellen, et al.
Publicado: (2021)

PET Radiopharmaceuticals for Alzheimer’s Disease and Parkinson’s Disease Diagnosis, the Current and Future Landscape
por: Uzuegbunam, Bright Chukwunwike, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ora6clj802pkq6ijm6apk9vbmq